tetano
Editor, Senior Moderator
World J Clin Cases
. 2021 May 26;9(15):3546-3558.
doi: 10.12998/wjcc.v9.i15.3546.
Effectiveness of adjunctive corticosteroid therapy in patients with severe COVID-19: A retrospective cohort study
Bin Xiong[SUP] 1 [/SUP], Li-Min He[SUP] 2 [/SUP], Yuan-Yuan Qin[SUP] 3 [/SUP], Hu Du[SUP] 1 [/SUP], Zhu Zhan[SUP] 1 [/SUP], Yi-Hong Zhou[SUP] 3 [/SUP], Yao-Kai Chen[SUP] 3 [/SUP], An Zhang[SUP] 4 [/SUP]
Affiliations
Abstract
Background: The effectiveness of adjunctive corticosteroid use in patients with coronavirus disease 2019 (COVID-19) remains inconclusive.
Aim: To investigate the effectiveness of adjunctive corticosteroid therapy in patients with severe COVID-19.
Methods: We conducted a retrospective analysis of the difference in several outcomes between patients with severe COVID-19 who received corticosteroid therapy (the corticosteroid group) and patients with severe COVID-19 who did not receive corticosteroid therapy (the non-corticosteroid group).
Results: Seventy-five patients were included in this study. Of these, 47 patients were in the corticosteroid group and 28 patients were in the non-corticosteroid group. There were no differences between the two groups in the total length of hospital stay, the length of intensive care unit stay, high-flow oxygen days, non-invasive ventilator days, invasive ventilation days, and mortality rate. Total lesion volume ratio, consolidation volume ratio and ground-glass opacity volume ratio in the corticosteroid group decreased significantly on day 14, while those in the non-corticosteroid group did not show a significant decrease.
Conclusion: Our results show that adjunctive corticosteroid use did not significantly improve clinical outcomes in severe COVID-19 patients, but might promote the absorption of pulmonary lesions. Larger multicenter randomized controlled studies may be needed to confirm this.
Keywords: COVID-19; Corticosteroid; Outcomes; SARS-CoV-2.
. 2021 May 26;9(15):3546-3558.
doi: 10.12998/wjcc.v9.i15.3546.
Effectiveness of adjunctive corticosteroid therapy in patients with severe COVID-19: A retrospective cohort study
Bin Xiong[SUP] 1 [/SUP], Li-Min He[SUP] 2 [/SUP], Yuan-Yuan Qin[SUP] 3 [/SUP], Hu Du[SUP] 1 [/SUP], Zhu Zhan[SUP] 1 [/SUP], Yi-Hong Zhou[SUP] 3 [/SUP], Yao-Kai Chen[SUP] 3 [/SUP], An Zhang[SUP] 4 [/SUP]
Affiliations
- PMID: 34046454
- PMCID: PMC8130064
- DOI: 10.12998/wjcc.v9.i15.3546
Abstract
Background: The effectiveness of adjunctive corticosteroid use in patients with coronavirus disease 2019 (COVID-19) remains inconclusive.
Aim: To investigate the effectiveness of adjunctive corticosteroid therapy in patients with severe COVID-19.
Methods: We conducted a retrospective analysis of the difference in several outcomes between patients with severe COVID-19 who received corticosteroid therapy (the corticosteroid group) and patients with severe COVID-19 who did not receive corticosteroid therapy (the non-corticosteroid group).
Results: Seventy-five patients were included in this study. Of these, 47 patients were in the corticosteroid group and 28 patients were in the non-corticosteroid group. There were no differences between the two groups in the total length of hospital stay, the length of intensive care unit stay, high-flow oxygen days, non-invasive ventilator days, invasive ventilation days, and mortality rate. Total lesion volume ratio, consolidation volume ratio and ground-glass opacity volume ratio in the corticosteroid group decreased significantly on day 14, while those in the non-corticosteroid group did not show a significant decrease.
Conclusion: Our results show that adjunctive corticosteroid use did not significantly improve clinical outcomes in severe COVID-19 patients, but might promote the absorption of pulmonary lesions. Larger multicenter randomized controlled studies may be needed to confirm this.
Keywords: COVID-19; Corticosteroid; Outcomes; SARS-CoV-2.